Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
Appointed director
VOLITIONRX LTD (VNRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2023 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted to report that we submitted a Breakthrough Device Designation Request to the FDA in June for our Nu.Q ® technology in relation to sepsis. This was a milestone moment in our company’s history and for the first time we are in active ..."
07/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/30/2023 8-K Appointed a new director
Docs: "2015 Stock Incentive Plan, as amended"
06/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time"
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time"
02/14/2023 SC 13G/A Lagoda Investment Management, L.P. reports a 6.5% stake in VolitionRX Limited
11/25/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
09/30/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/16/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
08/02/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "Underwriting Agreement, by and between VolitionRx Limited and Newbridge Securities Corporation",
"Opinion of Stradling, Yocca, Carlson & Rauth, P.ßC",
"VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, July 28, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Volition. In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual siz...",
"HENDERSON, Nevada, July 29, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The offering is expected to close on or about August 2, 2022, subject to ...",
"HENDERSON, Nevada, August 2, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter’s overallotment option, at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering were $6.9 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corp..."
08/01/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/28/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/14/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/20/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/30/2022 10-K Annual Report for the period ended December 31, 2021
03/30/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00 am U.S. Eastern Time"
03/29/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "AUSTIN, Texas, March 29, 2022 /PRNewswire/ --"
02/14/2022 SC 13G/A Lagoda Investment Management, L.P. reports a 6.1% stake in VolitionRX Limited
11/10/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/10/2021 8-K Quarterly results
Docs: "Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time"
11/09/2021 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy